Navigation Links
BioVex Agrees SPA With the FDA for a Pivotal Study With OncoVEX(GM-CSF) in Metastatic Melanoma and Announces Presentation of Phase II Results at ASCO
Date:4/22/2008

FDA agrees to first SPA for an oncolytic product

WOBURN, Mass., April 22 /PRNewswire/ -- BioVex Inc, a biotechnology company developing clinical stage treatments for cancer and the prevention of infectious disease, announced today that the U.S. Food and Drug Administration (FDA) has approved the design of a single, pivotal, Phase III clinical trial evaluating its lead product, OncoVEX(GM-CSF) in previously treated patients with metastatic melanoma. The agreement was made under the Special Protocol Assessment (SPA) procedure.

BioVex is currently concluding a 50-patient Phase II trial for OncoVEX(GM-CSF) as stand alone therapy in patients with unresectable Stage IIIc and Stage IV metastatic melanoma. The trial was designed to measure overall objective response, which is defined as a complete response (CR), where disease is completely eliminated, or partial response (PR), where there is a >30% reduction in disease burden. Interim results from the study demonstrated a highly encouraging rate of durable objective response with multiple patients with metastatic disease at enrollment having been declared disease free following therapy. The full study has been accepted for oral presentation at ASCO on June 1st where the results will be presented.

The Phase III study design agreed with the FDA follows directly from the study design successfully employed in Phase II. The Phase III study will also enroll previously treated patients with unresectable stage IIIc and stage IV disease using OncoVEX(GM-CSF) as monotherapy. The primary efficacy endpoint will also be response rate-based; the primary objective being to demonstrate a statistically significant increase in the rate of objective responses maintained for six months or more, in comparison to control therapy (subcutaneously administered(GM-CSF). The study is intended to enroll 360 evaluable patients randomized such that 240 patients receive OncoVEX(GM-CSF) and 120 patients receive contro
'/>"/>

SOURCE BioVex Inc
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Arpida Provides Further Comments on the Pivotal Phase III Trials
2. Anesiva Announces Pivotal Phase 3 Clinical Trial of Adlea(TM) for Reducing Post-Surgical Pain Following Total Knee Replacement
3. PLC Systems Receives FDA Approval to Commence Pivotal Study Of RenalGuard(TM) In the U.S.
4. Independent Data Safety Monitoring Board Recommends Continuation of Sangarts Pivotal Phase III Trials of Hemospan(R) Following Second Interim Review
5. DuraHeart(TM) LVAS Receives Conditional Approval for US Pivotal Trial
6. Arbios Receives Conditional Approval from the FDA to Initiate Pivotal Clinical Trial for SEPET(TM)
7. Accumetrics Announces $28.8 Million Financing and Initiation of Pivotal Clinical Trial
8. Keryx Biopharmaceuticals Completes SUN-MICRO Phase 3 Pivotal Trial
9. Anthera Enters Into Manufacturing Agreements for Varespladib in Preparation for Pivotal Phase III Trials
10. Vical Receives Payment from AnGes MG for Allovectin-7(R) Phase 3 Pivotal Trial
11. First Patient Enrolled in Cogentus Pharmaceuticals Pivotal Phase 3 Trial of Novel Combination Medicine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... TAUNTON, Massachusetts , 21. Mai 2013 ... Inc. („OSI"), die die Firmen OMNIlife science® ... Tochtergesellschaften zählt, hat zwei neue, erfahrene Mitglieder ... Mayer , eine erfahrene Führungspersönlichkeit aus ... übernehmen. David Johnson , ...
(Date:5/21/2013)...  Tom Daulton, CEO of Mammotome, a division of Devicor ... the Cincinnati chapter of the Association ... local top executive who is also a breast cancer survivor, ... in March of 2010. Daulton will be presented with the ... Huntington Bank, on May 22. The ACG Deal ...
(Date:5/21/2013)... and PHILADELPHIA , May 21, 2013 ... its new corporate image and impressive new product developments at ... . "After ten years of unerring focus on product ... felt the need to mark the occasion," said founding director ... we have some interesting developments of benefit to our clients ...
Breaking Medicine Technology:Orthopaedic Synergy Inc. meldet bedeutenden Zuwachs im Vorstand 2Orthopaedic Synergy Inc. meldet bedeutenden Zuwachs im Vorstand 3Tom Daulton, Mammotome CEO, Named ACG Dealmaker of the Year 2Tom Daulton, Mammotome CEO, Named ACG Dealmaker of the Year 3Pi2 Solutions' 10th Anniversary Heralds New Corporate Image as Platinum Sponsor of SLA PHT Meeting in Philadelphia 2Pi2 Solutions' 10th Anniversary Heralds New Corporate Image as Platinum Sponsor of SLA PHT Meeting in Philadelphia 3
... , HOPKINTON, Mass. , Jan. 25 ... provider of tools and services for drug discovery and life ... and several new platform innovations at the LabAutomation 2010 conference ... the flexibility of its predecessors with powerful new innovations including: ...
... , NEW YORK , Jan. 25 ... therapeutics for chronic fibrotic and metabolic diseases, today announced the ... financing by its majority shareholder Genextra S.p.A. , Dr. ... is recognition of the success we have had advancing our ...
Cached Medicine Technology:Caliper Life Sciences Introduces Sciclone(R) G3 Liquid Handler 2Caliper Life Sciences Introduces Sciclone(R) G3 Liquid Handler 3Intercept Pharmaceuticals Raises $25 Million Series B Financing 2Intercept Pharmaceuticals Raises $25 Million Series B Financing 3
(Date:5/21/2013)... GA (PRWEB) May 21, 2013 Patients of ... Care who have lost teeth due to gum disease and ... surgery for gum disease treatment with laser gum surgery. ... which have the highest success rate out of all tooth ... (LANAP) is a relatively new procedure cleared by the Food ...
(Date:5/21/2013)... Kan. Primary care practice transformation on a ... care reform efforts aimed at achieving better outcomes, ... emerging evidence that transformation toward the patient-centered medical ... health care environment, the U.S. Department of Health ... Quality funded 14 studies to learn more about ...
(Date:5/21/2013)... May 21, 2013 Parker Waichman LLP, ... of victims injured by defective medical devices, is addressing ... Joint Surgery on May 15, 2013. The study found ... identify complications that occur in patients with metal-on-metal hip ... ( http://www.jbjs.org/article.aspx?articleid=1684770 ) , “We’ve known ...
(Date:5/21/2013)... 21, 2013 Artisan Business Group ... Summit: Dealmakers Conference in Long Beach, California on ... on exploring alternative finance through EB-5 immigrant investors ... legal and economic information, and updates to project ... within the EB-5 industry. , "Our goal ...
(Date:5/21/2013)... 2013 Arizona State University is ... to develop their ideas into solutions, products and ... The university is recruiting participants for AREA48 (Applied ... that provides early-stage entrepreneurs with opportunities to access ... to anyone, ASU is particularly seeking participation from ...
Breaking Medicine News(10 mins):Health News:Shenk Dental Care Stimulates Bone Growth for Gum Disease Patients Seeking Dental Implants with Laser Gum Surgery in Atlanta, GA 2Health News:AHRQ-funded journal supplement offers lessons on primary care practice transformation 2Health News:AHRQ-funded journal supplement offers lessons on primary care practice transformation 3Health News:AHRQ-funded journal supplement offers lessons on primary care practice transformation 4Health News:AHRQ-funded journal supplement offers lessons on primary care practice transformation 5Health News:AHRQ-funded journal supplement offers lessons on primary care practice transformation 6Health News:Parker Waichman LLP Comments on New Study Showing that MRI is Useful for Predicting Failure of Metal-on-Metal Hip Implants 2Health News:Parker Waichman LLP Comments on New Study Showing that MRI is Useful for Predicting Failure of Metal-on-Metal Hip Implants 3Health News:Artisan Business Group to Host EB-5 Investment Conference in Long Beach, California 2Health News:ASU Launches Summer Program for Aspiring Entrepreneurs, Innovators and Inventors 2Health News:ASU Launches Summer Program for Aspiring Entrepreneurs, Innovators and Inventors 3Health News:ASU Launches Summer Program for Aspiring Entrepreneurs, Innovators and Inventors 4
... the ban on mercury based flu vaccines given to pregnant ... six weeks . This decision was made due to a ... free children's vaccine is manufactured by Sanofi pasteur, and the ... speed up production to meet the state's need. ,The ...
... new artificial pump along with the intake of certain drugs ... say scientists in Britain.// ,The temporary pumps, known ... patients with severe heart failure while they await transplantation, reported ... on the work of one of the heart's four chambers, ...
... biggest killer disease in the UK during the 1800s has made ... to 2005. //Th number of cases have been rising from the ... , causing great concern to government health agencies. ,The ... Louis Stevenson , was thought to have been conquered by very ...
... unhappy lot because nearly 50 percent of the clan is ... in their careers.// A new study has claimed that nearly ... of chemicals, soaps and shampoos that render constantly moist hands., ... careers, unable to carry on with their jobs when the ...
... abused in early stages of life may grow up to ... University of Chicago. //This study was conducted on baby rhesus ... may lead to the production of less seratonin, a chemical ... causes anxiety and depression.It may also lead to impulsive aggression ...
... down with acute symptoms of dengue, later confirmed positive for ... alarming figure of 741. ,Nearly 31 deaths have ... Peshawar. The National Institute of Health (NIH) has reiterated via ... the disease are pouring in from all over Pakistan which ...
Cached Medicine News:Health News:New Device May Help Heal A Failing Heart 2Health News:TB Returns , Sharp Rise In Cases In UK 2Health News:Hair-raising issues of hairdressers 2Health News:An abused child may grow up to be an abusive parent 2Health News:An abused child may grow up to be an abusive parent 3
Valleylab Surgistat II generator provides exceptional performance, reliability, and safety benefits in a compact, easy to use unit....
Sabre 180, 230V, 50Hz is a powerful niche generator....
Microcontroller-based isolated electrosurgical generator, designed for all general purpose surgical procedures. Unit includes: Instant Response technology, adaptive REM system, isolated output, CEM c...
Maddox rod and occluder...
Medicine Products: